BRAF and neoplasm: This could be related to several factors: different BRAF mutations have different prognostic value [34]; CRC intratumor heterogeneity and the complex interactions with other molecular alterations can influence the therapeutic response; BRAF mutation in CRC is difficult to target and several resistance mechanisms have been discovered, but some of them still remain unknown; tumor stage can influence the prognostic value of BRAF mutations.